Top

Published in:

Open Access 01-05-2015 | Review

Pathophysiology of diabetic dyslipidaemia: where are we?

Author: Bruno Vergès

Published in: Diabetologia | Issue 5/2015

Abstract

Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes mellitus, with a two- to fourfold increase in cardiovascular disease risk compared with non-diabetic individuals. Abnormalities in lipid metabolism that are observed in the context of type 2 diabetes are among the major factors contributing to an increased cardiovascular risk. Diabetic dyslipidaemia includes not only quantitative lipoprotein abnormalities, but also qualitative and kinetic abnormalities that, together, result in a shift towards a more atherogenic lipid profile. The primary quantitative lipoprotein abnormalities are increased triacylglycerol (triglyceride) levels and decreased HDL-cholesterol levels. Qualitative lipoprotein abnormalities include an increase in large, very low-density lipoprotein subfraction 1 (VLDL₁) and small, dense LDLs, as well as increased triacylglycerol content of LDL and HDL, glycation of apolipoproteins and increased susceptibility of LDL to oxidation. The main kinetic abnormalities are increased VLDL₁ production, decreased VLDL catabolism and increased HDL catabolism. In addition, even though LDL-cholesterol levels are typically normal in patients with type 2 diabetes, LDL particles show reduced turnover, which is potentially atherogenic. Although the pathophysiology of diabetic dyslipidaemia is not fully understood, the insulin resistance and relative insulin deficiency observed in patients with type 2 diabetes are likely to contribute to these lipid changes, as insulin plays an important role in regulating lipid metabolism. In addition, some adipocytokines, such as adiponectin or retinol-binding protein 4, may also contribute to the development of dyslipidaemia in patients with type 2 diabetes.

Norgaard ML, Andersen SS, Schramm TK et al (2010) Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction—a nationwide study. Diabetologia 53:1612–1619PubMed

Mulnier HE, Seaman HE, Raleigh VS et al (2008) Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia 51:1639–1645PubMed

Turner RC, Millns H, Neil HA et al (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823–828PubMedCentralPubMed

McEwen LN, Karter AJ, Waitzfelder BE et al (2012) Predictors of mortality over 8 years in type 2 diabetic patients: Translating Research Into Action for Diabetes (TRIAD). Diabetes Care 35:1301–1309PubMedCentralPubMed

Eliasson B, Cederholm J, Eeg-Olofsson K, Svensson AM, Zethelius B, Gudbjornsdottir S (2011) Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish National Diabetes Register. Diabetes Care 34:2095–2100PubMedCentralPubMed

Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733–749PubMed

Chahil TJ, Ginsberg HN (2006) Diabetic dyslipidemia. Endocrinol Metab Clin North Am 35:491–510, vii–viii

Vergès B (2005) New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 31:429–439PubMed

Olofsson SO, Stillemark-Billton P, Asp L (2000) Intracellular assembly of VLDL: two major steps in separate cell compartments. Trends Cardiovasc Med 10:338–345PubMed

10.

Vergès B (2010) Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis 211:353–360PubMed

11.

Fisher EA, Pan M, Chen X et al (2001) The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J Biol Chem 276:27855–27863PubMed

12.

Ji A, Wroblewski JM, Cai L, de Beer MC, Webb NR, van der Westhuyzen DR (2012) Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI. J Lipid Res 53:446–455PubMedCentralPubMed

13.

Rader DJ (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116:3090–3100PubMedCentralPubMed

14.

Pillois X, Gautier T, Bouillet B et al (2012) Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease. J Lipid Res 53:1200–1209PubMedCentralPubMed

15.

Cianflone K, Paglialunga S, Roy C (2008) Intestinally derived lipids: metabolic regulation and consequences—an overview. Atheroscler Suppl 9:63–68PubMed

16.

Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB (2004) Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 27:1680–1687PubMed

17.

Tsubakio-Yamamoto K, Matsuura F, Koseki M et al (2008) Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun 375:390–394PubMed

18.

Vergès B, Petit JM, Duvillard L et al (2006) Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol 26:1364–1369PubMed

19.

Lewis GF, Uffelman KD, Szeto LW, Steiner G (1993) Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 42:833–842PubMed

20.

Malmstrom R, Packard CJ, Caslake M et al (1998) Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 47:779–787PubMed

21.

Brown AM, Gibbons GF (2001) Insulin inhibits the maturation phase of VLDL assembly via a phosphoinositide 3-kinase-mediated event. Arterioscler Thromb Vasc Biol 21:1656–1661PubMed

22.

Sparks JD, Sparks CE, Adeli K (2012) Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 32:2104–2112PubMed

23.

Sparks JD, O’Dell C, Chamberlain JM, Sparks CE (2013) Insulin-dependent apolipoprotein B degradation is mediated by autophagy and involves class I and class III phosphatidylinositide 3-kinases. Biochem Biophys Res Commun 435:616–620PubMedCentralPubMed

24.

Karimian PN, Adeli K (2011) Insulin silences apolipoprotein B mRNA translation by inducing intracellular traffic into cytoplasmic RNA granules. Biochemistry 50:6942–6950

25.

Altomonte J, Cong L, Harbaran S et al (2004) Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 114:1493–1503PubMedCentralPubMed

26.

Laatsch A, Merkel M, Talmud PJ, Grewal T, Beisiegel U, Heeren J (2009) Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. Atherosclerosis 204:105–111PubMed

27.

Chait A, Bierman EL, Albers JJ (1979) Low-density lipoprotein receptor activity in cultured human skin fibroblasts. Mechanism of insulin-induced stimulation. J Clin Invest 64:1309–1319PubMedCentralPubMed

28.

Ruotolo G, Parlavecchia M, Taskinen MR et al (1994) Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity. Diabetes Care 17:6–12PubMed

29.

Perret B, Mabile L, Martinez L, Terce F, Barbaras R, Collet X (2002) Hepatic lipase: structure/function relationship, synthesis, and regulation. J Lipid Res 43:1163–1169PubMed

30.

Riemens SC, van Tol A, Stulp BK, Dullaart RP (1999) Influence of insulin sensitivity and the TaqIB cholesteryl ester transfer protein gene polymorphism on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities and their response to hyperinsulinemia in non-diabetic men. J Lipid Res 40:1467–1474PubMed

31.

Doucet J, Le Floch JP, Bauduceau B, Verny C (2012) GERODIAB: glycaemic control and 5-year morbidity/mortality of type 2 diabetic patients aged 70 years and older: 1. Description of the population at inclusion. Diabetes Metab 38:523–530PubMed

32.

Wang J, Stancakova A, Soininen P et al (2012) Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men. J Intern Med 272:562–572PubMed

33.

Arca M, Pigna G, Favoccia C (2012) Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. Curr Vasc Pharmacol 10:684–686PubMed

34.

Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433–438PubMed

35.

Axelsen M, Smith U, Eriksson JW, Taskinen MR, Jansson PA (1999) Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes. Ann Intern Med 131:27–31PubMed

36.

Florez H, Ryder E, Campos G et al (1999) Women relatives of Hispanic patients with type 2 diabetes are more prone to exhibit metabolic disturbances. Invest Clin 40:127–142PubMed

37.

Ooi EM, Ng TW, Chan DC, Watts GF (2009) Plasma markers of cholesterol homeostasis in metabolic syndrome subjects with or without type-2 diabetes. Diabetes Res Clin Pract 85:310–316PubMed

38.

Simonen PP, Gylling HK, Miettinen TA (2002) Diabetes contributes to cholesterol metabolism regardless of obesity. Diabetes Care 25:1511–1515PubMed

39.

Brindisi MC, Guiu B, Duvillard L et al (2012) Liver fat content is associated with an increase in cholesterol synthesis independent of statin therapy use in patients with type 2 diabetes. Atherosclerosis 224:465–468PubMed

40.

Caballero F, Fernandez A, De Lacy AM, Fernandez-Checa JC, Caballeria J, Garcia-Ruiz C (2009) Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol 50:789–796PubMed

41.

Shojaee-Moradie F, Ma Y, Lou S, Hovorka R, Umpleby AM (2013) Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol. Diabetes 62:4063–4069PubMedCentralPubMed

42.

Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P (2007) Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J Lipid Res 48:1336–1342PubMed

43.

Phillips C, Mullan K, Owens D, Tomkin GH (2006) Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition. Atherosclerosis 187:57–64PubMed

44.

Nogueira JP, Maraninchi M, Beliard S et al (2012) Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes. Arterioscler Thromb Vasc Biol 32:1039–1044PubMed

45.

Annuzzi G, De NC, Iovine C et al (2004) Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 24:2397–2402PubMed

46.

Duez H, Lamarche B, Valero R et al (2008) Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 117:2369–2376PubMed

47.

Adiels M, Matikainen N, Westerbacka J et al (2012) Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis 222:222–228PubMed

48.

Taskinen MR, Nikkila EA, Kuusi T, Harmo K (1982) Lipoprotein lipase activity and serum lipoproteins in untreated type 2 (insulin-independent) diabetes associated with obesity. Diabetologia 22:46–50PubMed

49.

Olivieri O, Bassi A, Stranieri C et al (2003) Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 44:2374–2381PubMed

50.

Watanabe N, Taniguchi T, Taketoh H et al (1999) Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care 22:152–156PubMed

51.

Nappo F, Esposito K, Cioffi M et al (2002) Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 39:1145–1150PubMed

52.

Anderson RA, Evans ML, Ellis GR et al (2001) The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis 154:475–483PubMed

53.

Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Vergès B (2000) Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Investig 30:685–694

54.

Kissebah AH, Alfarsi S, Evans DJ, Adams PW (1982) Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 31:217–225PubMed

55.

Ginsberg HN, Zhang YL, Hernandez-Ono A (2005) Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 36:232–240PubMed

56.

Malmstrom R, Packard CJ, Caslake M et al (1997) Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40:454–462PubMed

57.

Adiels M, Boren J, Caslake MJ et al (2005) Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 25:1697–1703PubMed

58.

Pont F, Duvillard L, Florentin E, Gambert P, Vergès B (2002) Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity. Arterioscler Thromb Vasc Biol 22:1726–1732PubMed

59.

Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PH (2002) Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 51:1041–1046PubMed

60.

Adiels M, Taskinen MR, Packard C et al (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49:755–765PubMed

61.

Sondergaard E, Sorensen LP, Rahbek I, Gormsen LC, Christiansen JS, Nielsen S (2012) Postprandial VLDL-triacylglycerol secretion is not suppressed in obese type 2 diabetic men. Diabetologia 55:2733–2740PubMed

62.

Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC et al (2002) Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem 277:793–803PubMed

63.

Chirieac DV, Collins HL, Cianci J, Sparks JD, Sparks CE (2004) Altered triglyceride-rich lipoprotein production in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab 287:E42–E49PubMed

64.

Qiu W, Kohen-Avramoglu R, Rashid-Kolvear F et al (2004) Overexpression of the endoplasmic reticulum 60 protein ER-60 downregulates apoB100 secretion by inducing its intracellular degradation via a nonproteasomal pathway: evidence for an ER-60-mediated and pCMB-sensitive intracellular degradative pathway. Biochemistry 43:4819–4831PubMed

65.

Kuriyama H, Yamashita S, Shimomura I et al (1998) Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation. Hepatology 27:557–562PubMed

66.

Kamagate A, Qu S, Perdomo G et al (2008) FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 118:2347–2364PubMedCentralPubMed

67.

Schwarz JM, Linfoot P, Dare D, Aghajanian K (2003) Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 77:43–50PubMed

68.

Ishii S, Iizuka K, Miller BC, Uyeda K (2004) Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci U S A 101:15597–15602PubMedCentralPubMed

69.

Ferre P, Foufelle F (2007) SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm Res 68:72–82PubMed

70.

Duvillard L, Florentin E, Pont F et al (2011) Endogenous chronic hyperinsulinemia does not increase the production rate of VLDL apolipoprotein B: proof from a kinetic study in patients with insulinoma. J Clin Endocrinol Metab 96:2163–2170PubMed

71.

Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H (2007) Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 292:E829–E835PubMed

72.

Taskinen MR, Adiels M, Westerbacka J et al (2011) Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol 31:2144–2150PubMed

73.

Hegele RA, Ginsberg HN, Chapman MJ et al (2014) The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2:655–666PubMed

74.

Garvey WT, Kwon S, Zheng D et al (2003) Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52:453–462PubMed

75.

Palmer AM, Nova E, Anil E et al (2005) Differential uptake of subfractions of triglyceride-rich lipoproteins by THP-1 macrophages. Atherosclerosis 180:233–244PubMed

76.

Stahlman M, Pham HT, Adiels M et al (2012) Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes. Diabetologia 55:1156–1166PubMed

77.

Hyysalo J, Gopalacharyulu P, Bian H et al (2014) Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity. Diabetes 63:312–322PubMed

78.

Mamo JC, Szeto L, Steiner G (1990) Glycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia 33:339–345PubMed

79.

Saheki S, Hitsumoto Y, Murase M, Takeuchi N, Uchida K (1993) In vitro degradation of very low density lipoprotein from diabetic patients by lipoprotein lipase. Clin Chim Acta 217:105–114PubMed

80.

Stolinski M, Alam S, Jackson NC et al (2008) Effect of 6-month supervised exercise on low-density lipoprotein apolipoprotein B kinetics in patients with type 2 diabetes mellitus. Metabolism 57:1608–1614PubMed

81.

Duvillard L, Florentin E, Lizard G et al (2003) Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care 26:1540–1544PubMed

82.

Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D (1982) Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes 31:283–291PubMed

83.

Rabbani N, Chittari MV, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ (2010) Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes 59:1038–1045PubMedCentralPubMed

84.

Steinbrecher UP, Witztum JL (1984) Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 33:130–134PubMed

85.

Makita T, Tanaka A, Nakano T, Nakajima K, Numano F (1999) Importance of glycation in the acceleration of low density lipoprotein (LDL) uptake into macrophages in patients with diabetes mellitus. Int Angiol 18:149–153PubMed

86.

Kita T, Kume N, Minami M et al (2001) Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci 947:199–205PubMed

87.

Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM (1992) LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 12:1496–1502PubMed

88.

Vakkilainen J, Steiner G, Ansquer JC et al (2003) Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107:1733–1737PubMed

89.

Tani M, Kawakami A, Mizuno Y et al (2011) Small dense LDL enhances THP-1 macrophage foam cell formation. J Atheroscler Thromb 18:698–704PubMed

90.

Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J (1996) Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124:261–271PubMed

91.

Vakkilainen J, Makimattila S, Seppala-Lindroos A et al (2000) Endothelial dysfunction in men with small LDL particles. Circulation 102:716–721PubMed

92.

Vergès B, Brun JM, Vaillant G et al (1992) Influence of obesity and hypertriglyceridaemia on the low HDL2-cholesterol level and on its relationship with prevalence of atherosclerosis in type 2 diabetes. Diabete Metab 18:289–297PubMed

93.

Golay A, Zech L, Shi MZ, Chiou YA, Reaven GM, Chen YD (1987) High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab 65:512–518PubMed

94.

Duvillard L, Pont F, Florentin E, Gambert P, Vergès B (2000) Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 152:229–237PubMed

95.

Despres JP, Ferland M, Moorjani S et al (1989) Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese women. Arteriosclerosis 9:485–492PubMed

96.

Vergès B, Adiels M, Boren J et al (2014) Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicentre tracer kinetic study. J Clin Endocrinol Metab 99:4281–4290PubMed

97.

Gordon SM, Davidson WS, Urbina EM et al (2013) The effects of type 2 diabetes on lipoprotein composition and arterial stiffness in male youth. Diabetes 62:2958–2967PubMedCentralPubMed

98.

Plomgaard P, Dullaart RP, de Vries R, Groen AK, Dahlbäck B, Nielsen LB (2009) Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects. J Intern Med 266:258–267PubMed

99.

Karuna R, Park R, Othman A et al (2011) Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 219:855–863PubMed

100.

Patel DC, Albrecht C, Pavitt D et al (2011) Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. PLoS ONE 6:e22142PubMedCentralPubMed

101.

Passarelli M, Tang C, McDonald TO et al (2005) Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes 54:2198–2205PubMed

102.

Mauldin JP, Nagelin MH, Wojcik AJ et al (2008) Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetes mellitus. Circulation 117:2785–2792PubMedCentralPubMed

103.

Nobecourt E, Jacqueminet S, Hansel B et al (2005) Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48:529–538PubMed

104.

Persegol L, Vergès B, Foissac M, Gambert P, Duvillard L (2006) Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 49:1380–1386PubMed

105.

Sorrentino SA, Besler C, Rohrer L et al (2010) Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121:110–122PubMed

106.

Bagdade JD, Lane JT, Subbaiah PV, Otto ME, Ritter MC (1993) Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus. Atherosclerosis 104:69–77PubMed

107.

Passarelli M, Catanozi S, Nakandakare ER et al (1997) Plasma lipoproteins from patients with poorly controlled diabetes mellitus and “in vitro” glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins. Diabetologia 40:1085–1093PubMed

108.

Bouillet B, Gautier T, Blache D et al (2014) Glycation of apolipoprotein C1 impairs its CETP inhibitory property: pathophysiological relevance in patients with type 1 and type 2 diabetes. Diabetes Care 37:1148–1156PubMed

109.

Desrumaux C, Athias A, Bessede G et al (1999) Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 19:266–275PubMed

110.

de Vries R, Dallinga-Thie GM, Smit AJ, Wolffenbuttel BH, van Tol A, Dullaart RP (2006) Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima–media thickness in type 2 diabetes mellitus. Diabetologia 49:398–404

111.

Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A (2008) Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 114:361–374

112.

Cnop M, Havel PJ, Utzschneider KM et al (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459–469PubMed

113.

Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH (2005) Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 54:795–802PubMed

114.

Annuzzi G, Bozzetto L, Patti L et al (2010) Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response: a possible link with diabetic postprandial dyslipidemia. Metabolism 59:567–574PubMed

115.

Qiao L, Zou C, van der Westhuyzen DR, Shao J (2008) Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes 57:1824–1833PubMedCentralPubMed

116.

Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T (2007) Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 92:2712–2719PubMed

117.

Vergès B, Guiu B, Cercueil JP et al (2012) Retinol-binding protein 4 is an independent factor associated with triglycerides and a determinant of very low-density lipoprotein-apolipoprotein B100 catabolism in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 32:3050–3057PubMed

Title: Pathophysiology of diabetic dyslipidaemia: where are we?
Author: Bruno Vergès
Publication date: 01-05-2015
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 5/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-015-3525-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pathophysiology of diabetic dyslipidaemia: where are we?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

In vivo targeted delivery of ANGPTL8 gene for beta cell regeneration in rats

Serum albumin concentration and incident type 2 diabetes risk: new findings from a population-based cohort study

Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance

Genetic and phenotypic correlations between surrogate measures of insulin release obtained from OGTT data

Human islet distribution programme for basic research: activity over the last 5 years

High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page